Skip to content
Human Parvovirus B19 IgM Lateral flow dipstick kit 4473

Human Parvovirus B19 IgM Lateral flow dipstick kit 4473

$487.00

Summary

  • Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
  • Human Parvovirus B19 IgM Lateral flow dipstick kit 4473
  • Suitable for IgM detection
  • Ready-to-use
  • 20 tests
SKU: 4473 Category: Tags: , ,
Weight1 lbs
Dimensions9 × 5 × 2 in
target

Human Parvovirus B19 IgM

species reactivity

Human Parvovirus B19

applications

Lateral flow (dipstick)

assay type

Indirect & qualitative

available sizes

20 test kits

Human Parvovirus B19 IgM Lateral flow dipstick kit 4473

kit
Assay type
Sandwich assay, lateral flow (dipstick)
Research area
Infectious Disease
Sample type
Serum, plasma, whole blood
Components
10X Wash Buffer100 mL
TMB Substrate40 mL
Milk Powder5 g
Instructions for Use1 Each
Evaluation Form1 Each
Test Strips2 kits of [2 Vials x 10 Each]
Anti-Human IgM Conjugate500 μL
Positive Control140 μL
Negative Control140 μL
Storage
Store at 2-8°C.
Additional information
Mikrogen recomLine Parvovirus B19 Test

The Mikrogen recomLine Parvovirus B19 tests allow an indication of the time of infection due to the reactivity patterns of the recombinant antigens and the possibility to detect avidity determination of the IgG antibodies.

The determination of antibodies against the NS-1 antigen can be helpful in clarifying persistent parvovirus B19 infections. By using VP-2 particles, a presentation of conformational epitopes to the otherwise presented linear epitopes is achieved.

Advantages
  • Separate detection of IgG and IgM antibodies with antibody class control on the test strip.
  • Band pattern and avidity determination allow conclusions on infection status.
  • Parvovirus B19 infections during the last 4 weeks can be reliably excluded.
  • Excellent diagnostic quality due to internal controls and the use of VP2 particles.
  • Easy and clear interpretation, featuring easy-to-read banding patterns.
  • Partial and full automation, software-based evaluation (recomScan), and integration with the laboratory information system are possible.
  • Highest sensitivity and specificity due to the use of recombinant antigens.
Bands
AntigenAbbreviationSize (kDa)
Main capsid antigen (conformational epitopes)VP-2p65
N-terminal half of the structural proteins VP-1 and VP-2VP-N60
VP-1 specific segment (differentiation from VP-2)VP-1S31
Main capsid antigen (linear epitopes)VP-2r56
C-terminal half of the structural proteins VP-1 and VP-2VP-C42
Non-structural protein NS-1NS-175
target relevance
Organism
Parvovirus B19
Structure and strains
Human parvovirus B19, generally referred to as B19 virus (B19V), parvovirus B19 or sometimes erythrovirus B19, is the first (and until 2005 the only) known human virus in the family Parvoviridae, genus Erythroparvovirus; it measures only 23 26 nm in diameter. Human parvovirus b19 is a below-species classification of Erythroparvovirus primate1. The name is derived from Latin parvum, meaning small, reflecting the fact that B19 ranks among the smallest DNA viruses. B19 virus is most known for causing disease in the pediatric population; however, it can also affect adults. It is the classic cause of the childhood rash called fifth disease or erythema infectiosum, or "slapped cheek syndrome".
Disease
With a diameter of 18-26 nm, the worldwide distributed Parvovirus B19 belongs to the smallest human pathogens. Its capsid is made up of 95% of the structural protein VP2. The remaining 5% consists of VP1.

In many cases, Parvovirus B19 infections remain clinically asymptomatic. Infected children may develop erythema infectiosum, also named fifth disease. After an incubation period of four to 14 days garland-shaped exanthemas spread from the face downwards. The rash, in adults possibly accompanied by arthralgia in the small joints, may last for up to three weeks. Current studies in Germany indicate that 10-20% of children under three years of age have already had an infection with the virus. In adults, the seroprevalence increases to 70%. In pregnant women with primary Parvovirus B19 infection the virus is transmitted to the fetus and may lead to severe complications. In general, the regular course of an infection is limited by the synthesis of neutralizing antibodies. In immunosuppressed patients or patients with chronic haemolytic anaemia, infection may elicit severe clinical consequences with aplastic crisis, which can have fatal consequences.
Detection and diagnosis
As a consequence of the variable clinical symptoms which may be associated with Parvovirus B19 infection, a clinical diagnosis should be supported by the demonstration of virus specific antibodies.

Publications

pmidtitleauthorscitation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

relevant to this product
4473 protocol
#
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Related Products